Market Overview

UPDATE: Goldman Sachs Reinstates Neutral on BioMed Realty as Acquisitions Broaden Their Portfolio

Share:
Related BMR
UPDATE: Stifel Downgrades BioMed Realty Trust On Valuation
High-Yield REITs Show Strength As U.S. 10-Year Treasury Falls Below 2%

In a report published on Friday, Goldman Sachs analyst Matthew Rand reinstated a Neutral rating on BioMed Realty (NYSE: BMR) and maintained its $21 price target on the company.

In the report, Goldman Sachs commented that, "We have removed the Not Rated designation from BioMed Realty shares. We rate BMR as a Neutral, with a 12-month, $21 price target. We continue to think that BMR's most relevant comp is Alexandria Real Estate Equities (ARE), which we also rate Neutral. In addition, we think that Digital Realty Trust (DLR, Buy) offers better value as well as better growth within the more capital-intensive, slow-growth property sectors."

BioMed Realty closed on Thursday at $20.50

Latest Ratings for BMR

DateFirmActionFromTo
Feb 2015Stifel NicolausDowngradesBuyHold
Nov 2014Stifel NicolausMaintainsBuy
Oct 2014Mizuho SecuritiesInitiates Coverage onBuy

View More Analyst Ratings for BMR
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Matthew RandAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BMR)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content